A B S T R A C T Anticonvulsant therapy of seizure disorders in man is
A B S T R A C T Anticonvulsant therapy of seizure disorders in man is associated with the development of complications involving bone and mineral metabolism including hypocalcemia, elevated serum immunoreactive parathyroid hormone levels, and increased amounts of unmineralized bone or osteoid. The latter has been attributed to a reduction in serum-25-hydroxycholecalciferol levels resulting from increased hepatic metabolism of vitamin D. Using an in vitro recycling hepatic perfusion system, we have demonstrated that 3 .3±0.2%/h, P < 0.02). Addition of phenobarbital or its major metabolite, p-hydroxyphenobarbital, directly to the perfusion apparatus had no effect on 25 -hydroxylation system(s) by a metabolite of phenobarbital other than p-hydroxyphenobarbital and/or by metabolic alterations resulting from phenobarbital therapy.
INTRODUCTION
Hypocaleemia, elevated serum immunoreactive parathyroid hormone levels, and increased amounts of Received for publication 16 February 1979 and in revised form 31 May 1979.
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J. Clin. Invest. C) The American Society for unmineralized bone or osteoid are frequent complications attending anticonvulsant therapy of seizure disorders in man (1) (2) (3) (4) (5) (6) (7) . This disordered bone and mineral metabolism resulting from chronic phenobarbital and dilantin treatment has been attributed to decreased circulating levels of 25-hydroxyvitamin D3 (2-4) and increased metabolism of vitamin D3 to more polar degradation products by the liver (8) (9) (10) . However, normal to high circulating levels of 1,25-dihydroxyvitamin D3, the most potent metabolite of the vitamin, have recently been reported in patients receiving anticonvulsant drugs (11) , and phenobarbital has been demonstrated to increase the 1-hydroxylation of 25-hydroxyvitamin D3 by the kidney in vitro (12) . These observations, coupled with the finding that phenobarbital and dilantin blunt the bone rudiment response to parathyroid hormone and 1,25-dihydroxyvitamin D3 (13) , have led to the postulate that the disordered bone and mineral metabolism attending anticonvulsant therapy may be a consequence of a direct inhibitory effect of the drugs on bone, and not a result of the altered hepatic metabolism of vitamin D3 (14) . The hepatic 25-hydroxylation of vitamin D3 has been demonstrated to occur at two subcellular sites, the microsomes (15) and the mitochondria (16) . Although the microsomal 25-hydroxylation of vitamin D3 is not blunted by inhibitors of the cytochromne P450 system (17) , it has been reported that administration of phenobarbital to humans and animals lead to induction of microsomal oxidase enzymes, presumably of the P450 system (8, 18) , with resultant increased catabolism of vitamin D3 and 25-hydroxyvitamin D3, to polar, inactive products (8) (9) (10) . In contrast, phenobarbital has been documented to increase the mitochonidrial 25 -hydroxylation of vitamin D (16) .
The purpose of these studies was to investigate the net effect of phenobarbital on the microsomal and mitochondrial 25- Three protocols for the in vitro perfusion of the rachitic rat liver were undertaken. In the first protocol, 32 rachitic untreated rats were sacrificed by phlebotomy under light ether anesthesia and the blood used for the liver perfusate (vide infra). Four rats were injected with phenobarbital and four received the vehicle for 5 d. These latter animals served as the liver donors. In the second protocol, 18 rachitic rats were treated with phenobarbital for 5 d before sacrifice by phlebotomy and 18 rats were given the vehicle. The blood from each of these groups was used for the perfusion of a liver from an untreated rachitic rat. In the final protocol, either phenobarbital, 1.5 ,ug/ml, or its major derivative, p-hydroxyphenobarbital (21), 0.55 .g/ml, was directly added to the perfusate at the initiation of the liver perfusion. Experimental and control livers were simultaneously perfused in independent chambers at a rate of 15 ml/min. The perfusate was recycled during the course of the 4-h experiments.
[3H]vitamin D3, 0.5 ,uCi, purchased from New England Nuclear (Boston, Mass.) was added to each perfusate at zero time. Humidity and temperature were maintained in the chambers at 80-90% and 37°C, respectively.
The surgical removal and perfusion of the livers were performed as described (22) . The and control perfusates after either 2 or 3 h of perfusion.
Portions of perfusate were removed at 15-min intervals over the ensuing hour and the BSP concentration of the perfusate determined (25) . Clearance of the dye over the 60-min period was expressed as nanomolar per gram liver per minute. Lactate and pyruvate (26) concentrations were quantitated in the perfusate at zero time, and after 30,60, 120, 180, and 240 min of perfusion. Portions of perfusate were removed at the designated times and centrifuged at 2,000 g for 10 min at 2°C. Lactate and pyruvate levels in the supernate were determined and expressed as the lactate:pyruvate ratio.
After 4 h, the perfusion was terminated and the perfusate and bile extracted in a methanol:chloroform mixture (27, 28) . 3H-25-OH D3 production was determined by chromatography of the lipid fraction of the perfusate with Sephadex LH-20-100 (Pharmacia Fine Chemicals, Piscataway, N. J.). Columns were packed to 35 cm and eluted with 50:50 hexane:chloroform. 2-ml fractions were collected. The percentage of total radioactivity appearing as 3H-25-OH D3 during the 4-h perfusion was determined and expressed as percent per hour 3H-25-OH D3 production. The 3H-25-OH D3 obtained from the Sephadex LH-20 columns was pooled and run on a high-pressure liquid chromatograph, 0.4 x 30 cm am porisil column (Varian Instruments, Palo Alto, Calif.). The flow rate was 1 ml/min and 1 ml fractions were collected. A 95:5 and 97.5:2.5 hexane: isopopyl alcohol solvent system was used. In both instances, 3H-25-OH D3 obtained from the Amersham Corp. (Arlington Heights, Ill.) and purified by chromatography on a Sephadex LH-20 column was the standard. The 3H-25-OH D3 produced by the liver was mixed with cold 25-hydroxyvitamin D3 and the UV absorbance at 263 nm determined along with the radioactivity of each fraction.
The liver was also homogenized in normal saline and extracted in the methanol:chloroform mixture. The liver was perfused with Krebs-Ringer bicarbonate buffer before extraction to remove trace isotope present in the vascular system. The amount of [3H]vitamin D3 and 3H-25-OH D3 in the lipid fraction of the hepatic extraction was quantitated by Sephadex LH-20 chromatography and expressed as disintegration per minute per milligram liver protein.
The amount of [3H]vitamin D3 metabolites conjugated to glucuronides in the aqueous fraction of the bile was determined by treating the aqueous fraction with 1,500 U of marine mollusk ,8-glucuronidase for 48 h at 37°C as described (29) . This fraction was then extracted in the chloroform:methanol mixture and the radioactivity in the resultant aqueous and lipid fractions determined.
All data is expressed as the mean±SEM, and the probability of difference was determined with the paired t test.
RESULTS
Phenobarbital treatment (65 mg/kg body wt) for 5 d resulted in circulating levels ofphenobarbital of 1.5 ,Lg/ ml, a concentration that is within the therapeutic range for human seizure disorders. Phenobarbital did not affect the in vivo concentration of 25-hydroxyvitamin D3, the level in both treated and control rachitic rats being <1 ng/ml. The body weight of the rats whose livers were used for the perfusion were similar in the phenobarbital-treated and control groups (210±26 vs.
205±30 g). Likewise, the liver weights of the two groups were similar (8.95+3.12 vs. 8 The lactate:pyruvate ratios were determined in the perfusate throughout the 4-h experimental period. Initially, the ratios were elevated at zero time reflecting that period between the phlebotomy of the animals and the initiation of the perfusion. However, after only 30 min of perfusion the ratio closely approximated the normal of 10, where it remained during the first 3-h of the perfusion. After 4 h of perfusion, the ratio was slightly elevated in both phenobarbital-treated and control livers at 16.
[3H]Vitamin D3 metabolism. When phenobarbital was administered to rachitic rats and the liver of the treated animal perfused for 4 h, the production of 3H-25-OH D3 increased (4.3±0.3 vs. 3.3+0.2%/h, P < 0.025).
A typical Sephadex LH-20 chromatograph is illustrated in Fig. 1 , where the 3H-25-OH D3 represented 20 phenobarbital-treated liver, and only 11.9% of the radioactivity of the control liver. To insure that the polar metabolite collected in fraction 10-20 of the Sephadex LH-20 column (Fig. 1) 2) . In the first instance, the 3H-25-OH D3 co-eluted in the 5th ml with cold 25-hydroxyvitamin D3 and with the standard 3H-25-OH D3. When the solvent system was 97.5:2.5 hexane:isopropyl alcohol, the metabolites all co-eluted in the 10th ml. Thus, the polar metabolite produced by the liver during the 4-h perfusion was 3H-25-OH D3. Although phenobarbital treatment increased the production of 3H-25-OH D3, it had no effect on the distribution of [3H]vitamin D3 metabolites in either the aqueous (31, The blood of animals treated with phenobarbital for 5 d was then used to perfuse an untreated rachitic liver. The production of 3H-25-OH D3 was increased after 4 h of perfusion (4.6+0.5 vs. 3.3±0.2%/h, P < 0.02) with blood obtained from animals treated with phenobarbital. However when phenobarbital, 1.5,tg/ml, or its major metabolite p-hydroxyphenobarbital, 0.55 ,.g/ml, were added directly to the perfusate at zero-time, neither stimulated the production of 3H-25-OH D3.
Phenobarbital treatment also altered the distribution ofvitamin D in the liver. Whereas, the amount of3H-25-OH D3 in hepatic tissue was not affected by phenobarbital (3.7±0.3 vs. 3.4±0.4 dpm/mg liver protein), treatment was associated with a significant decrease in the content of [3H]vitamin D3 (11.7±0.4 vs. 17.5±0.7 dpm/mg liver protein, P < 0.001).
DISCUSSION
The alterations in bone and mineral metabolism consequent to prolonged therapy with anticonvulsant medications are complex. The hypocalcemia, elevated levels of circulating immunoreactive parathyroid hormone, and increased amounts ofunmineralized bone or osteoid attending anticonvulsant therapy (1) (2) (3) (4) (5) (6) (7) have been attributed to derangements in vitamin D metabolism resulting in decreased serum concentrations of 25-hydroxyvitamin D3 (2-4). These decreased concentrations have been thought to be secondary to increased hepatic degradation of the 25-hydroxy metabolite to more polar by-products with resultant increased biliary excretion of the vitamin (8) (9) (10) . However, using a recycling in vitro hepatic perfusion system, we have shown that phenobarbital treatment of rats for 5 (24) . These results are similar to our values of 19.5 and 20.5 nM/g liver per min in phenobarbital-treated and control rachitic perfused livers, where only a loading dose was administered. Finally, the lactate:pyruvate ratio of both preparations was similar and approximated the normal ratio of 10. The lactate: pyruvate ratio is an indicator of both ongoing aerobic glycolysis as well as a normal "coupling" of the anaerobic and aerobic pathways. Thus, both the phenobarbital and control preparations were viable, and the effects of phenobarbital on 25-hydroxyvitamin D3 production cannot be attributed to altered tissue integrity.
Previous studies have demonstrated that the 25-hydroxylation of vitamin D3 occurs at two subcellular sites, the microsomes (15) and the mitochondria (16), the latter responding to phenobarbital with an increase in the production of 25-hydroxyvitamin D3 (16) . In contrast, phenobarbital has been reported to inhibit the microsomal 25-hydroxylation of [3H]vitamin D3 (32) . Although the whole liver perfusion preparation does not allow us to comment upon which subcellular 25-hydroxylation site(s) are affected by phenobarbital treatment, it does demonstrate that the net effect of acute therapy is to increase the production of 25-hydroxyvitamin D3 by the liver without affecting biliary radioactivity. Furthermore, the data demonstrate that this effect is secondary to a metabolite ofphenobarbital other than p-hydroxyphenobarbital and/or metabolic changes consequent to phenobarbital treatment. The results of this acute therapy regimen cannot be extrapolated to explain the metabolic effects of chronic phenobarbital treatment in humans, however the study indicates that the hepatic perfusion model may be used to further investigate the effects of long-term phenobarbital treatment on the hepatic metabolism of vitamin D.
